Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

See Locations Near You

Summary

this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added
the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen)
all patients receive all three drugs; there is no placebo

View Full Description

Full Description

Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible.
Patients with brain metastases, squamous histology, or hemoptysis are excluded.
All patients must give informed consent.
Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeated every 21 days for 6 cycles

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy
Stage IV disease or stage IIIB with a malignant pleural effusion
measurable or evaluable disease
Performance status 0 or 1 (ECOG)
adequate renal, hepatic, and bone marrow function
adequate recovery from previous surgery or radiotherapy
informed consent

Exclusion Criteria:

brain metastases
squamous (epidermoid) histology
hemoptysis
central airway disease
Pancoast tumors
previous chemotherapy or biologic therapy for lung cancer
prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS
pregnant or nursing women

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

45

Study ID:

NCT00150657

Recruitment Status:

Unknown status

Sponsor:

St. John Providence Health System

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Providence Cancer Institute
Southfield Michigan, 48075, United States More Info
Michael J Kraut, MD
Contact
248-849-8155
[email protected]
Howard Terebelo, DO
Contact
248-552-0620
Michael J Kraut, MD
Principal Investigator
Howard Terebelo, DO
Sub-Investigator
Anibal Drelichman, MD
Sub-Investigator
Robert Bloom, MD
Sub-Investigator
Lyle Goldman, MD
Sub-Investigator
Judie Goodman, DO
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

45

Study ID:

NCT00150657

Recruitment Status:

Unknown status

Sponsor:


St. John Providence Health System

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider